|
1
|
Hundal R and Shaffer EA: Gallbladder
cancer: Epidemiology and outcome. Clin Epidemiol. 6:99–109.
2014.PubMed/NCBI
|
|
2
|
Eslick GD: Epidemiology of gallbladder
cancer. Gastroenterol Clin North Am. 39:307–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Misra S, Chaturvedi A, Misra NC and Sharma
ID: Carcinoma of the gallbladder. Lancet Oncol. 4:167–176. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Caldow Pilgrim CH, Groeschl RT, Quebbeman
EJ and Gamblin TC: Recent advances in systemic therapies and
radiotherapy for gallbladder cancer. Surg Oncol. 22:61–67. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller LH and Su X: Artemisinin: Discovery
from the Chinese herbal garden. Cell. 146:855–858. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu YX, Wu W, Liang YJ, Jie ZL, Wang H,
Wang W and Huang YX: New uses for old drugs: The tale of
artemisinin derivatives in the elimination of Schistosomiasis
japonica in China. Molecules. 19:15058–15074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ho WE, Peh HY, Chan TK and Wong WS:
Artemisinins: Pharmacological actions beyond antimalarial.
Pharmacol Ther. 142:126–139. 2014. View Article : Google Scholar
|
|
8
|
Lu JJ, Chen SM, Zhang XW, Ding J and Meng
LH: The anticancer activity of dihydroartemisinin is associated
with induction of iron-dependent endoplasmic reticulum stress in
colorectal carcinoma HCT116 cells. Invest New Drugs. 29:1276–1283.
2011. View Article : Google Scholar
|
|
9
|
Chen T, Li M, Zhang R and Wang H:
Dihydroartemisinin induces apoptosis and sensitizes human ovarian
cancer cells to carboplatin therapy. J Cell Mol Med. 13:1358–1370.
2009. View Article : Google Scholar
|
|
10
|
Wang J, Zhang B, Guo Y, Li G, Xie Q, Zhu
B, Gao J and Chen Z: Artemisinin inhibits tumor lymphangiogenesis
by suppression of vascular endothelial growth factor C.
Pharmacology. 82:148–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sundar SN, Marconett CN, Doan VB,
Willoughby JA Sr and Firestone GL: Artemisinin selectively
decreases functional levels of estrogen receptor-alpha and ablates
estrogen-induced proliferation in human breast cancer cells.
Carcinogenesis. 29:2252–2258. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weifeng T, Feng S, Xiangji L, Changqing S,
Zhiquan Q, Huazhong Z, Peining Y, Yong Y, Mengchao W, Xiaoqing J
and Wan-Yee L: Artemisinin inhibits in vitro and in vivo invasion
and metastasis of human hepatocellular carcinoma cells.
Phytomedicine. 18:158–162. 2011. View Article : Google Scholar
|
|
13
|
Morrissey C, Gallis B, Solazzi JW, Kim BJ,
Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL and Sasaki T:
Effect of artemisinin derivatives on apoptosis and cell cycle in
prostate cancer cells. Anticancer Drugs. 21:423–432. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lei YY, Wang WJ, Mei JH and Wang CL:
Mitogen-activated protein kinase signal transduction in solid
tumors. Asian Pac J Cancer Prev. 15:8539–8548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Q and Yang Z: Expression of
phospho-ERK1/2 and PI3-K in benign and malignant gallbladder
lesions and its clinical and pathological correlations. J Exp Clin
Cancer Res. 28:652009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jinawath A, Akiyama Y, Yuasa Y and
Pairojkul C: Expression of phosphorylated ERK1/2 and homeodomain
protein CDX2 in cholangiocarcinoma. J Cancer Res Clin Oncol.
132:805–810. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
18
|
Tran KQ, Tin AS and Firestone GL:
Artemisinin triggers a G1 cell cycle arrest of human Ishikawa
endometrial cancer cells and inhibits cyclin-dependent kinase-4
promoter activity and expression by disrupting nuclear factor-kB
transcriptional signaling. Anticancer Drugs. 25:270–281. 2014.
View Article : Google Scholar :
|
|
19
|
Tin AS, Sundar SN, Tran KQ, Park AH,
Poindexter KM and Firestone GL: Antiproliferative effects of
artemisinin on human breast cancer cells requires the downregulated
expression of the E2F1 transcription factor and loss of E2F1-target
cell cycle genes. Anticancer Drugs. 23:370–379. 2012. View Article : Google Scholar
|
|
20
|
Jiang Z, Chai J, Chuang HH, Li S, Wang T,
Cheng Y, Chen W and Zhou D: Artesunate induces G0/G1 cell cycle
arrest and iron-mediated mitochondrial apoptosis in A431 human
epidermoid carcinoma cells. Anticancer Drugs. 23:606–613. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Willoughby JA Sr, Sundar SN, Cheung M, Tin
AS, Modiano J and Firestone GL: Artemisinin blocks prostate cancer
growth and cell cycle progression by disrupting Sp1 interactions
with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting
CDK4 gene expression. J Biol Chem. 284:2203–2213. 2009. View Article : Google Scholar :
|
|
22
|
Zhao Y, Jiang W, Li B, Yao Q, Dong J, Cen
Y, Pan X, Li J, Zheng J, Pang X and Zhou H: Artesunate enhances
radiosensitivity of human non-small cell lung cancer A549 cells via
increasing no production to induce cell cycle arrest at G2/M phase.
Int Immunopharmacol. 11:2039–2046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Steinbrück L, Pereira G and Efferth T:
Effects of artesunate on cytokinesis and G2/M cell cycle
progression of tumour cells and budding yeast. Cancer Genomics
Proteomics. 7:337–346. 2010.
|
|
24
|
Semczuk A and Jakowicki JA: Alterations of
pRb1-cyclin D1-cdk4/6-p16 (INK4A) pathway in endometrial
carcinogenesis. Cancer Lett. 203:1–12. 2004. View Article : Google Scholar
|
|
25
|
Singh NP and Lai HC: Artemisinin induces
apoptosis in human cancer cells. Anticancer Res. 24:2277–2280.
2004.PubMed/NCBI
|
|
26
|
Nam W, Tak J, Ryu JK, Jung M, Yook JI, Kim
HJ and Cha IH: Effects of artemisinin and its derivatives on growth
inhibition and apoptosis of oral cancer cells. Head Neck.
29:335–340. 2007. View Article : Google Scholar
|
|
27
|
Hou J, Wang D, Zhang R and Wang H:
Experimental therapy of hepatoma with artemisinin and its
derivatives: In vitro and in vivo activity, chemosensitization and
mechanisms of action. Clin Cancer Res. 14:5519–5530. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamachika E, Habte T and Oda D:
Artemisinin: An alternative treatment for oral squamous cell
carcinoma. Anticancer Res. 24:2153–2160. 2004.PubMed/NCBI
|
|
29
|
Disbrow GL, Baege AC, Kierpiec KA, Yuan H,
Centeno JA, Thibodeaux CA, Hartmann D and Schlegel R:
Dihydroartemisinin is cytotoxic to papillomavirus-expressing
epithelial cells in vitro and in vivo. Cancer Res. 65:10854–10861.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Efferth T: Mechanistic perspectives for
1,2,4-trioxanes in anticancer therapy. Drug Resist Updat. 8:85–97.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Hu W, Zhang JL, Wu XH and Zhou HJ:
Dihydroartemisinin induces autophagy and inhibits the growth of
iron-loaded human myeloid leukemia K562 cells via ROS toxicity.
FEBS Open Bio. 2:103–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haynes RK, Cheu KW, N'Da D, Coghi P and
Monti D: Considerations on the mechanism of action of artemisinin
antimalarials: Part 1-the 'carbon radical' and 'heme' hypotheses.
Infect Disord Drug Targets. 13:217–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar
|
|
34
|
Oh SH and Lim SC: A rapid and transient
ROS generation by cadmium triggers apoptosis via caspase-dependent
pathway in HepG2 cells and this is inhibited through
N-acetylcysteine-mediated catalase upregulation. Toxicol Appl
Pharmacol. 212:212–223. 2006. View Article : Google Scholar
|
